Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.26M | -44.10M | -43.44M | -55.47M | -81.66M |
| Total Depreciation and Amortization | 33.00K | 23.00K | 13.00K | 3.00K | -- |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 186.00K | 36.07M | 36.07M |
| Total Other Non-Cash Items | 1.60M | 1.62M | 1.44M | -19.27M | 12.74M |
| Change in Net Operating Assets | 1.61M | -53.00K | 3.43M | -505.00K | 689.00K |
| Cash from Operations | -41.02M | -42.51M | -38.37M | -39.16M | -32.16M |
| Capital Expenditure | -200.00K | -200.00K | -200.00K | -183.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -49.70M | -69.87M | -19.52M | -34.52M | -- |
| Cash from Investing | -49.90M | -70.07M | -19.72M | -34.71M | -- |
| Total Debt Issued | 0.00 | 0.00 | 7.50M | 17.47M | 17.47M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 42.08M | 42.07M | 42.00M | 2.00K | 3.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.58M | 3.97M | 105.51M | 97.37M | 97.37M |
| Cash from Financing | 45.67M | 46.05M | 155.01M | 114.84M | 114.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -45.25M | -66.54M | 96.91M | 40.97M | 82.69M |